AstraZeneca on Tuesday released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease, boosting hopes that it could generate multibillion-dollar sales for the company. The biologic medicine, tozorakimab, is under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027….
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases. The science behind rare disease drug development is changing fast, and with it, so is the financial engine that drives it all. This month saw the launch of…
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients, the company announced Thursday. The drug, marketed as Bixlenvo, is aimed at patients whose virus is already under control but who remain on complicated treatment regimens. It could also appeal…
Nikos Pekiaridis | Nurphoto | Getty Images A court ruling this week in favor of Gilead Sciences could significantly impact a burgeoning class of health programs in the U.S. that federal authorities say are illegally importing medications from overseas. Last year, a CNBC investigation found that these programs — called alternative funding programs, or AFPs…
My top 10 things to watch Monday, Aug. 3 1. Peace talks between the U.S. and Iran are back on the menu, so oil prices are falling. WTI crude is off more than 5%, trading below $80 a barrel this morning. Stock futures are higher across the board, led by the Dow . Within our…
AstraZeneca shares dropped as much as 7% after a report that the U.K.’s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion. AstraZeneca declined to comment. Bristol Myers Squibb didn’t immediately respond to a request to comment outside of…
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its purchase of Medarex in July added a key drug for metastic melanoma that’s in Phase III trials. The drug has possible multiple indications – industry jargon for its ability to treat more…
Traders work on the floor of the New York Stock Exchange during morning trading on July 24, 2026 in New York City. Michael M. Santiago | Getty Images Investors are becoming more willing to increase their exposure to international equities, as concerns over the dominance of the “Magnificent Seven” technology giants encourage diversification away from…
Shares of AstraZeneca fell as much as 9% after a late stage clinical trial for an experimental heart disease failed to meet its target. The medicine, Wainua, did not reach its main goal of reducing deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo, the British drugmaker said in a press release…
The U.S. has launched an investigation into Germany’s pharma policies over what it referred to as “persistent underpayment” for medicines as the European country looks to limit spiraling healthcare costs, including spending on drugs. “President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development,”…
